2023 / 04

Next Paper
DOI: 10.47183/mes.2023.057
Copyright: © 2023 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Assessing biodistribution of biomedical cellular product based on human chondrocytes following implantation to BALB/C nude mice

Pikina AS1, Golubinskaya PA1, Ruchko ES2, Kozhenevskaya EV3, Pospelov AD3, Babayev AA3, Eremeev AV1,2
About authors

1 Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

2 Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, Russia

3 Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia

Correspondence should be addressed: Arina S. Pikina
Malaya Pirogovskaya, 1а, Moscow, 119435, Russia; ur.xednay@anikip.anira

About paper

Funding: the study was performed under the State Assignment “Chondrosphere”, R&D project ID АААА-А19-119052890054-4.

Acknowledgments: the authors express their gratitude to the research staff of the laboratory of cell biology, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of FMBA of Russia, for methodological support provided during the study.

Author contribution: Pikina AS — literature review, literature source collection and analysis, manuscript writing; Golubinskaya PA — data acquisition and analysis, manuscript editing; Ruchko ES — data acquisition and analysis; Kozhenevskaya EV — carrying out work at the vivarium; Pospelov AD — histological analysis; Babayev AA — animal experiment management; Eremeev AV — experimental design, final correction of the manuscript. All authors confirm compliance of authorship to ICMJE international criteria.

Compliance with the ethical standards: the study was approved by the Boethics Commission of the Lobachevsky State University of Nizhny Novgorod (protocol № 73 dated 17 April 2023).

Received: 2023-11-05 Accepted: 2023-12-17 Published online: 2023-12-31
|
  1. Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, et al. Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. Front Cell Dev Biol. 2020; 8: 547653. DOI: 10.3389/fcell.2020.547653.
  2. Kim J, Park J, Song SY, Kim E. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries. Regen Ther. 2022; 20: 126–37. DOI: 10.1016/j.reth.2022.04.004.
  3. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with ACI. N Engl J Med. 1994; 331 (14): 889–95.
  4. Fontana A, Bistolfi A, Crova M, Rosso F, Massazza G. Arthroscopic treatment of hip chondral defects: Autologous chondrocyte transplantation versus simple debridement —A pilot study. Arthrosc — J Arthrosc Relat Surg. 2012; 28 (3): 322–9. DOI: 10.1016/j.arthro.2011.08.304.
  5. Saris D, Price A, Widuchowski W, Bertrand-Marchand M, Caron J, Drogset JO, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: Two-year follow-up of a prospective randomized trial. Am J Sports Med. 2014; 42 (6): 1384–94. DOI: 10.1177/0363546514528093.
  6. Yoon KH, Yoo JD, Choi CH, Lee J, Lee JY, Kim SG, et al. Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial. Cartilage. 2021; 13 (1): 1092S–1104S. DOI: 10.1177/1947603520921448.
  7. Hoburg A, Niemeyer P, Laute V, Zinser W, Becher C, Kolombe T, et al. Matrix-Associated Autologous Chondrocyte Implantation with Spheroid Technology Is Superior to Arthroscopic Microfracture at 36 Months Regarding Activities of Daily Living and Sporting Activities after Treatment. Cartilage. 2021; 13 (1): 437S–448S. DOI: 10.1177/1947603519897290.
  8. Zscharnack M, Krause C, Aust G, Thümmler C, Peinemann F, Keller T, et al. Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). J Transl Med. 2015; 13 (1): 1–17. DOI: 10.1186/s12967-015-0517-x.
  9. Fickert S, Gerwien P, Helmert B, Schattenberg T, Weckbach S, Kaszkin-Bettag M, et al. One-Year Clinical and Radiological Results of a Prospective, Investigator-Initiated Trial Examining a Novel, Purely Autologous 3-Dimensional Autologous Chondrocyte Transplantation Product in the Knee. Cartilage. 2012; 3 (1): 27– 42. DOI: 10.1177/1947603511417616.
  10. Spherox. European Medicines Agency. [cited 2023 Oct 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spherox.
  11. Study Details. The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy. ClinicalTrials.gov. [cited 2023 Oct 26]. Available from: https://clinicaltrials.gov/study/NCT02539069?cond=Osteoarthritis&intr=Chondrocytes&page=2&rank=13.
  12. Choi NY, Kim BW, Yeo WJ, Kim HB, Suh DS, Kim JS, et al. Gel-type autologous chondrocyte (Chondron) implantation for treatment of articular cartilage defects of the knee. BMC Musculoskelet Disord. 2010; 11. DOI: 10.1186/1471-2474-11-103.
  13. Pathak S, Chaudhary D, Reddy KR, Acharya KKV, Desai SM. Efficacy and safety of CARTIGROW® in patients with articular cartilage defects of the knee joint: a four year prospective studys. Int Orthop. 2022; 46 (6): 1313–21. DOI: 10.1007/s00264-022-05369-2.
  14. Crowe R, Willers C, Cheng T, Wang L, Zheng MH. Evaluation of Intraoperative Retention of Autologous Chondrocytes on Type I/III Collagen Scaffold (Ortho-ACITM) for Cartilage Repair. J Foot Ankle Res. 2015; 8 (S2): 2015. DOI: 10.1186/1757-1146-8-s2-p10.
  15. Riedl M, Vadalà G, Papalia R, Denaro V. Three-dimensional, Scaffold-Free, Autologous Chondrocyte Transplantation: A Systematic Review. Orthop J Sport Med. 2020; 8 (9): 1–7. DOI: 10.1177/2325967120951152.
  16. Shah SS, Mithoefer K. Scientific Developments and Clinical Applications Utilizing Chondrons and Chondrocytes with Matrix for Cartilage Repair. Cartilage. 2021; 13 (1): 1195S–1205S. DOI: 10.1177/1947603520968884.
  17. Schubert T, Anders S, Neumann E. Long-term effects of chondrospheres on cartilage lesions in an autologous chondrocyte implantation model as investigated in the SCID mouse model. Int J Mol Med. 2009; 23 (4): 455–60. DOI: 10.3892/ijmm_00000151.
  18. Körsmeier K, Claßen T, Kamminga M, Rekowski J, Jäger M, Landgraeber S. Arthroscopic three-dimensional autologous chondrocyte transplantation using spheroids for the treatment of full-thickness cartilage defects of the hip joint. Knee Surgery, Sport Traumatol Arthrosc. 2016; 24 (6): 2032–7. DOI: 10.1007/ s00167-014-3293-x.
  19. Niemeyer P, Laute V, Zinser W, John T, Becher C, Diehl P, et al. Safety and efficacy of matrix-associated autologous chondrocyte implantation with spheroid technology is independent of spheroid dose after 4 years. Knee Surgery, Sport Traumatol Arthrosc. 2020; 28 (4): 1130–43. DOI: 10.1007/s00167-019-05786-8.
  20. Bartz C, Meixner M, Giesemann P, Roël G, Bulwin GC, Smink JJ. An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant. J Transl Med. 2016; 14 (1): 1–15. DOI: 10.1186/s12967-016-1065-8.
  21. Приказ Министерства здравоохранения Российской Федерации от 30 октября 2018 г. 512Н «Об утверждении правил надлежащей практики по работе с биомедицинскими клеточными продуктами». С. 1–71.
  22. Satué M, Schüler C, Ginner N, Erben RG. Intra-articularly injected mesenchymal stem cells promote cartilage regeneration, but do not permanently engraft in distant organs. Sci Rep. 2019; 9 (1): 1–10. DOI: 10.1038/s41598-019-46554-5.
  23. Marquina M, Collado JA, Pérez-Cruz M, Fernández-Pernas P, Fafián-Labora J, Blanco FJ, et al. Biodistribution and immunogenicity of allogeneic mesenchymal stem cells in a rat model of intraarticular chondrocyte xenotransplantation. Front Immunol. 2017; 8 (NOV): 1–14. DOI: 10.3389/fimmu.2017.01465.
  24. Erben RG, Silva-Lima B, Reischl I, Steinhoff G, Tiedemann G, Dalemans W, et al. White paper on how to go forward with cellbased advanced therapies in Europe. Tissue Eng — Part A. 2014; 20 (19–20): 2549–54. DOI: 10.1089/ten.tea.2013.0589.
  25. Federal'nyy zakon ot 23 iyunya 2016 g. №180-FZ «O biomeditsinskikh kletochnykh produktakh». Russian.
  26. GOST 33044-2014. Printsipy nadlezhashchey laboratornoy praktiki. Mezhgosudarstvennyy standart. Data vvedeniya: 1 avgusta 2015 g. Russian.
  27. Mironov AN, Bunyatyan ND. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. M.: Grif i K, 2012; 944 p. Russian.
  28. Eremeev AV, Belikova LD, Ruchko EA, Volovikov EA, Zubkova OA, Emelin AM, et al. Brain Organoid Generation from Induced Pluripotent Stem Cells in Home-Made Mini Bioreactors. J Vis Exp. 2021; 2021 (178). DOI: 10.3791/62987.
  29. Chen Y, Ma M, Teng Y, Cao H, Yang Y, Wang Y, et al. Efficient manufacturing of tissue engineered cartilage: In vitro by a multiplexed 3D cultured method. J Mater Chem B. 2020; 8 (10): 2082–95. DOI: 10.1039/c9tb01484e.
  30. Apelgren P, Amoroso M, Lindahl A, Brantsing C, Rotter N, Gatenholm P, et al. Chondrocytes and stem cells in 3D-bioprinted structures create human cartilage in vivo. PLoS One. 2017; 12 (12): 1–16. DOI: 10.1371/journal.pone.0189428.